KALRAY/EASYMILE
6.1.2021 18:02:21 CET | Business Wire | Press release
Autonomous technology provider EasyMile and intelligent processors supplier Kalray have deepened their relationship with the signature of a Memorandum of Understanding (MoU) formalizing their relationship to develop intelligent systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005553/en/
The partnership follows their work together in the ten-partner-strong ES3CAP collaborative project, led by Kalray and announced in 2019. The ES3CAP program, with a budget of €22.2 million over 3 years, aims to build a hardware and software platform intended for manufacturers developing critical applications requiring high computing capacity in the fields of aeronautics (aviation, flying cabs, UAVs), defense and, autonomous vehicles.
EasyMile’s technology interacts with all kinds of next-generation radars, cameras, and lidar sensors to autonomize a range of vehicles. Its vehicle-agnostic software makes it the partner of choice for global Original Equipment Manufacturers (OEMs). As a fabless company, EasyMile develops autonomous vehicle solutions that tackle identified use-cases very precisely using common-core, unique technology. EasyMile’s solutions require underlying platforms providing both safety and performance.
Benoit Perrin, Managing Director of EasyMile : “Safety and performance reliability are key to embedded systems. This collaboration with Kalray, which started with the ES3CAP program, matches the high criteria we expect of our partners and we are delighted to be working with them .”
Eric Baissus, CEO of Kalray : ”EasyMile is one of the most advanced companies delivering safe solutions for autonomous vehicles. For us, this collaboration is further evidence of the value that our MPPA® intelligent processors and SuperECU® solution can bring to easily build safe autonomous systems .”
Autonomous vehicles require ECUs (“Electronic Computing Unit”) capable of running a multitude of applications in parallel with no compromise on safety. Kalray’s SuperECU®, based on Kalray MPPA® Intelligent Processor, is a patented platform capable of providing both the demanding performance required to compute functions such as artificial intelligence algorithms but also to support multi-applications with different levels of criticality on the same chip. Kalray’s MPPA® processor is one of the rare solutions on the market to ensure complete freedom from interference between these applications, which is a key attribute in building safe systems.
In addition, Kalray intelligent processors are not only capable of executing AI algorithms but can also simultaneously execute a wide set of different processing such as mathematical algorithms, signal processing and networking software stacks. This heterogenous multi-processing capability is also a critical requirement for autonomous vehicles, and is a unique capability of Coolidge™, 3rd generation of MPPA® processor available now.
ABOUT EASYMILE
EasyMile provides software and complete solutions for driverless mobility and goods transportation. EasyMile partners with manufacturers to autonomize their vehicles with award-winning technology built on safety-by-design, ready for deployment today.
Since 2014, Easymile has become known for quality delivery and real-world deployments. Its proven technology has driven autonomous vehicles in 300+ locations in more than 30 countries: The EZ10 is the most deployed autonomous shuttle in the world. For material handling, TractEasy is a tow-truck solution optimizing supply chains with cross/indoor-outdoor, 24/7 material handling at factories and industrial sites.
With several mass operations around the world EasyMile was the first to deploy fully driverless at Level 4 of autonomous driving. It was also the first autonomous vehicle solutions provider to be ISO 9001 certified. At the core of EasyMile's cutting-edge sofware is a step-by-step approach to safety proven by a zero-collision record. EasyMile's future-ready technology specializes in robotics, computer vision and vehicle dynamics powered by deep learning. Among its customers leading transport operators, city authorities, airports, business parks, manufatcurers, factories, logistics centers and universities.
Headquartered in Toulouse, France, the company employs close to 250 highly qualified employees. In addition to the two founders, Gilbert Gagnaire and Philippe Ligier, EasyMile has investors who are also technical partners: Alstom, Continental and Bpifrance. www.easymile.com
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, leading provider in a new generation of processors specialized in Intelligent Data Processing from Cloud to Edge. Kalray MPPA® Intelligent Processors are able to capture and analyze on the fly massive data flows, and interact in real time with the outside world. These processors are capable of running demanding AI algorithms and simultaneously a wide set of different processing and control tasks such as intensive mathematical algorithms, signal processing, network or storage software stacks. Kalray’s Intelligent Processors can be deployed in fast-growing sectors from Cloud to Edge: modern data centers, 5G telecom networks, autonomous vehicles, healthcare equipment, industry 4.0, drones and robots… Kalray’s offering includes processors, acceleration cards and a software suite, for a broad spectrum of customers such as next generation data center equipment manufacturers and service providers, system integrators and consumer product manufacturers such as car makers. Founded in 2008 as a spin-off of CEA French lab, Kalray counts among its investors: Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance. Read more at: www.kalrayinc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005553/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom